Pharmacodynamic Modelling of Biomarker Data in Oncology

@inproceedings{Jackson2012PharmacodynamicMO,
  title={Pharmacodynamic Modelling of Biomarker Data in Oncology},
  author={Robert C. Jackson},
  booktitle={ISRN pharmacology},
  year={2012}
}
The development of pharmacodynamic (PD) biomarkers in oncology has implications for design of clinical protocols from preclinical data and for predicting clinical outcomes from early clinical data. Two classes of biomarkers have received particular attention. Phosphoproteins in biopsy samples are markers of inhibition of signalling pathways, target sites for many novel agents. Biomarkers of apoptosis in plasma can measure tumour cell killing by drugs in phase I clinical trials. The predictive… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 79 REFERENCES

Biomarkers of apoptosis

  • British Journal of Cancer
  • 2008
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

Prediction of the in vivo and clinical activity of drug combinations from in vitro data by differential pharmacodynamics

W. R. Greco, R. C. Jackson
  • Proceedings of the American Association for Cancer Research, 2008, abstract no. 4765.
  • 2008
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL